A blood test may tailor breast cancer treatment for older women

medicalxpress - For women age 70 and over with a common form of breast cancer, determining "the right size" of treatment can be challenging, in part because clinicians have limited tools to guide individualized treatment decisions. In a study published today in Clinical …

AI Summary: An ultra‑sensitive circulating tumor DNA assay shows promise in tailoring treatment for older breast cancer patients by detecting molecular signals that could guide therapy decisions and avoid unnecessary interventions. The blood test aims to refine risk stratification and personalize care where standard approaches often lack nuance, potentially sparing frail patients from overtreatment.


EBCC15: Less overtreatment through personalized radiotherapy and surveillance

3 months / medicalxpress

3 months / medicalxpress

3 months / oncodaily

3 months / medicalxpress


Liquid biopsies and sensors advancing cancer detection beyond breast

3 months / medicalxpress

3 months / oncodaily

3 months / oncodaily

3 months / medicalxpress


Other: biology and global burden stories

3 months / oncodaily

3 months / oncodaily

3 months / medicalxpress


Ultrasensitive ctDNA: tailoring breast cancer care for older patients

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / medicalxpress


All Other Stories

3 months / oncodaily

3 months / medicalxpress

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / nature





Related Stories


Journal retracts study claiming morning immunotherapy benefit / 14 days

Grail names new CEO as Bob Ragusa retires / 3 months

UCLA unveils low-cost blood test to detect multiple cancers from one sample / 3 months

Small study reports 100% one‑year survival after lung transplant / 21 hrs

High‑dose targeted radiation shows promise for huge bile duct tumors / 3 months

ctDNA blood test pinpoints who needs chemo after colorectal liver surgery / 4 days

Nine‑year CheckMate‑214 follow‑up confirms durable immunotherapy benefit / 7 days

StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Hearing Loss, Pharmaceuticals, Government Policy, Supply Chain and look for the RSS link.





NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.